Asgpr-binding compounds for the degradation of extracellular proteins
US-2024424108-A1 · Dec 26, 2024 · US
US9150563B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9150563-B2 |
| Application number | US-201414177000-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 10, 2014 |
| Priority date | Jul 8, 2008 |
| Publication date | Oct 6, 2015 |
| Grant date | Oct 6, 2015 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention provides a compound having excellent regulating action on blood lipid level. The present invention provides a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, etc., wherein A represents a 5-membered nitrogen-containing aromatic heterocyclyl group; R 1 represents COOH or the like; each R 2 represents an alkyl or the like; each R 3 represents an optionally substituted phenyl, an optionally substituted phenylalkyl, or the like; m represents 0, 1, 2, or 3; n represents 0 or 1; each of R 4 , R 5 , R 6 , and R 7 represents H, an alkyl, or the like; and B represents an optionally substituted naphthyl, an optionally substituted aromatic heterocyclyl, or a group represented by the following formula (II) wherein each of B 1 and B 2 represents an optionally substituted phenyl or an optionally substituted aromatic heterocyclyl.
Opening claim text (preview).
The invention claimed is: 1. 4-{3-[2-(4-Hydroxyphenyl)thiazol-5-yl]-2-fluoropropanoyl}amino-1-ethylpyrrole-3-carboxylic acid or a pharmacologically acceptable salt thereof. 2. A method for the treatment of a disease selected from hyperlipidemia, dyslipidemia, lipid metabolism abnormality, arteriosclerosis, hypertriglyceridemia, non-alcoholic steatohepatitis, or type II diabetes mellitus, which comprises administering a pharmaceutically effective amount of the co…
Related publications grouped by family.
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Answers are generated from the same data shown on this page.